Ph.D., Cornell University, Biometry, 1990.
My statistical methods research, in conjunction with colleagues and students, aims to improve the design and analysis of disease prevention trials, and observational studies. One emphasis has been the development of efficient design and analysis strategies for group randomized trials. Recent efforts include the proposal of a weighted permutation inference and a global test for multiple endpoints. Another emphasis has been the development of methods for cancer biomarker studies. Recent efforts include the development of guidelines for biomarker evaluation in cancer early detection, analysis methods for high dimensional data such as protein expression data from mass spectrometry, and Finite Mixture Models.
My applied research, in conjunction with colleagues and staff members, include the coordination of the national Early Detection Research Network (EDRN). This network includes 31 institutions in US with the mission to identify and validate biomarkers for early detection of cancer. We at FHCRC provide logistic, bioinformatics, and data management support for EDRN, and develop statistical methodology useful for EDRN mission.
I also collaborate with a large number of colleagues on variety of research projects including prostate cancer epidemiology and outcome, GI cancer etiology and biomarkers, community intervention trials, and occupational epidemiology.
(Reading, Writing, Speaking)
Chinese, Mandarin: (Fluent, Fluent, Fluent)
English: (Fluent, Fluent, Fluent)
American Statistical Association
Honors and Awards
1990, Cornell Graduate School Fellowship,
1988-1989, Cornell Outstanding Teaching Assistant Award,
1984, Cornell Graduate School Liu Memorial Award,
1997-2003, Affiliate Associate Professor, University of Washington, School of Public Health and Community Medicine, Biostatistics
1996-2001, Associate Member, Fred Hutchinson Cancer Research Center, Cancer Prevention Research
1990-1997, Affiliate Assistant Professor, University of Washington, School of Public Health and Community Medicine, Biostatistics
1990-1996, Assistant Member, Fred Hutchinson Cancer Research Center, Cancer Prevention Research
Methylation analysis in spontaneous sputum for lung cancer diagnosis.. Lung cancer (Amsterdam, Netherlands).. 2014.
Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.. 2014.
LOGISTIC REGRESSION ANALYSIS WITH STANDARDIZED MARKERS.. The annals of applied statistics. 7(3). 2013.
Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis.. Cancer epidemiology. 37(5):666-70.. 2013.
Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(9):2442-2450.. 2013.
Health beliefs associated with cervical cancer screening among vietnamese americans.. Journal of women's health (2002). 22(3):276-88.. 2013.
Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy.. Proteomics. Clinical applications. 7(5-6):327-336.. 2013.
Specific glycoforms of MUC5AC and endorepellin accurately distinguish mucinous from non-mucinous pancreatic cysts.. Molecular & cellular proteomics : MCP.. 2013.
Meat intake and cause-specific mortality: a pooled analysis of Asian prospective cohort studies.. The American journal of clinical nutrition.. 2013.
Association of variants in estrogen-related pathway genes with prostate cancer risk.. The Prostate. 73(12):1-10.. 2013.
The Early Detection Research Network's Specimen Reference Sets: Paving the Way for Rapid Evaluation of Potential Biomarkers.. Clinical chemistry. 59(1):68-74.. 2013.
A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.. Advances in anatomic pathology. 20(1):39-44.. 2013.
Pro-surfactant protein B as a biomarker for lung cancer prediction.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(36):4536-43.. 2013.
Response of serum and red blood cell folate concentrations to folic acid supplementation depends on methylenetetrahydrofolate reductase C677T genotype: results from a crossover trial.. Molecular nutrition & food research. 57(4):637-44.. 2013.
Association of body mass index and risk of death from pancreas cancer in Asians: findings from the Asia Cohort Consortium.. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP).. 2012.
Longitudinal multistage model for lung cancer incidence, mortality, and CT detected indolent and aggressive cancers.. Mathematical biosciences. 240(1):20-34.. 2012.
Evaluating Prognostic Accuracy of Biomarkers under Competing Risk.. Biometrics. 68(2):388-396.. 2012.
Evaluation of Known Oncoantibodies, HER2, p53, and Cyclin B1, in Prediagnostic Breast Cancer Sera.. Cancer prevention research (Philadelphia, Pa.).. 2012.
Structured penalties for functional linear models-partially empirical eigenvectors for regression.. Electronic journal of statistics. 6:323-353.. 2012.
Updating risk prediction tools: A case study in prostate cancer.. Biometrical journal. Biometrische Zeitschrift. 54(1):127-142.. 2012.
Conditional estimation after a two-stage diagnostic biomarker study that allows early termination for futility.. Statistics in medicine. 31(5):420-435.. 2012.